{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:03:06Z","timestamp":1782975786663,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications. This study aimed to evaluate the efficacy and safety of monoclonal antibodies (mAbs) against the RSV disease in premature infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across the PubMed, Cochrane Library, and Embase databases from inception through December 2025. Statistical analyses were performed using STATA software (version 15.0). Effect estimates were expressed as relative risk (RR) with corresponding 95% confidence intervals, and treatment rankings were evaluated using the surface under the cumulative ranking curve (SUCRA) probability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This Network Meta-analysis (NMA) included 7 randomized controlled trials involving 4 drugs and 11319 infants. Compared with the placebo, nirsevimab, motavizumab, and palivizumab have shown beneficial effects at reducing RSV-related hospitalization rates (RR, nirsevimab: 0.20, 95% CI: 0.09-0.45; motavizumab: 0.32 95% CI: 0.19-0.53; palivizumab: 0.43; 95% CI: 0.30-0.61) and Intensive Care Unit (ICU) admissions due to RSV infections (nirsevimab: 0.09, 95% CI: 0.01-0.87; motavizumab: 0.23, 95% CI: 0.08-0.65; palivizumab: 0.43, 95% CI: 0.21-0.90) in preterm infants. Nirsevimab was most likely to exert the best therapeutic effects, with the highest (SUCRA) values of 94.4% for RSV-related hospitalization rates and 89.1% for ICU admissions. No significant differences were found in mechanical ventilation use, deaths related to RSV Infections and drug-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nirsevimab, motavizumab, and palivizumab all reduced RSV-related hospitalizations and ICU admissions in preterm infants, with nirsevimab showing the greatest effect. However, further studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024583222<\/jats:ext-link>\n                      , identifier CRD42024583222.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1775795","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:01Z","timestamp":1782970441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Shunli","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]},{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"l5021","DOI":"10.1136\/bmj.l5021","article-title":"Respiratory syncytial virus infection in adults","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ (Clinical Research ed)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/s0140-6736(24)01716-1","article-title":"Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies","volume":"404","author":"Mazur","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1164\/rccm.202303-0568VP","article-title":"New interventions to prevent respiratory syncytial virus disease in infants-time for equitable global access","volume":"207","author":"Cunningham","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archpedi.1986.02140200053026","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1471-2334-12-95","article-title":"Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review","volume":"12","author":"Colosia","year":"2012","journal-title":"BMC Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e20180225","DOI":"10.1542\/peds.2018-0225","article-title":"Down syndrome and the risk of severe RSV infection: a meta-analysis","volume":"142","author":"Beckhaus","year":"2018","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S613","DOI":"10.1093\/infdis\/jiz150","article-title":"Acute lower respiratory infections associated with respiratory syncytial virus in children with underlying congenital heart disease: systematic review and meta-analysis","volume":"222","author":"Chaw","year":"2020","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","article-title":"Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data","volume":"403","author":"Wang","year":"2024","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/apa.13937","article-title":"National cohort study showed that infants with Down's syndrome faced a high risk of hospitalisation for the respiratory syncytial virus","volume":"106","author":"Grut","year":"2017","journal-title":"Acta Paediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.prrv.2009.06.003","article-title":"Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes","volume":"10","author":"Resch","year":"2009","journal-title":"Paediatr Respir Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/14712598.2011.608062","article-title":"A review of palivizumab and emerging therapies for respiratory syncytial virus","volume":"11","author":"Shadman","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2348135","DOI":"10.1080\/21645515.2024.2348135","article-title":"Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol","volume":"20","author":"Mallah","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1517\/14712590903287499","article-title":"Motavizumab for the prevention of respiratory syncytial virus infection in infants","volume":"9","author":"Gill","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14760584.2017.1333425","article-title":"Passive and active immunization against respiratory syncytial virus for the young and old","volume":"16","author":"Villafana","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 study group","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13584-018-0258-4","article-title":"Should we use palivizumab immunoprophylaxis for infants against respiratory syncytial virus?\u2014a cost-utility analysis","volume":"7","author":"Ginsberg","year":"2018","journal-title":"Isr J Health Policy Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/PCC.0b013e3182070990","article-title":"Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis","volume":"12","author":"Checchia","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","article-title":"Nirsevimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1775795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:03Z","timestamp":1782970443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1775795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":31,"alternative-id":["10.3389\/fped.2026.1775795"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1775795","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1775795"}}